Sovaldi launch trounces Incivek's

Share this article:

Gilead's launch of hepatitis C medication Sovaldi is looking turbo-charged: The Street's Adam Feuerstein tracked down IMS Health data that show new prescriptions rose around 70% the week ended January 10, but more important is the context: pulling a graph from ISI Group analyst Mark Schoenebaum, Feuerstein shows how Sovaldi's launch compares with that of Vertex's protease inhibitor Incivek. The comparison shows Sovaldi's initial push drwarfs that of once-novel Incivek—with prescription numbers more than triple those of Incivek's in the first five weeks of launch.

The FDA approved Gilead's drug in December. The regulator and drugmaker surprised analysts by including an all-oral gentotype-1 indication among the approved uses.

Schoenebaum noted at the time that he did not expect doctors would jump on the genotype 1 injection-free treatment option, saying there was little data to back this option, and that Gilead is expected to launch a “simpler (likely around $100K), cheaper, safer and more effective regimen in about a year,” for this same population.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.